biotech
Bio-AnalystSupplement research
person
arrow_backExplore/Riboflavin

Riboflavin

Selected research topic

Nutrient status

Some measured outcomes improved in human comparison studies. Read these findings with their populations and conditions.

Publications for this topic
2
Human comparison publications
1
Publications needing review
0

Findings in the studies

  • plasma tHcy

    • A better result than the comparison group was reported.

      What the comparison group used was not confirmed.

      Single ingredient
      Measurement and study conditions
      Study type
      Randomized controlled trial: subjects were randomly assigned to groups for comparison.
      Study population
      Human participants · Participant characteristics were not confirmed.
      Ingredients tested
      Single ingredient
      How results were compared
      Results were compared between groups.
      Measurement time
      Not confirmed.

  • riboflavin

    Research with unclear study subject or type
    • A change was reported, but the comparison could not be confirmed.
      Measurement and study conditions
      Study type
      Review
      Study population
      Study subject not identified
      Ingredients tested
      Unknown intervention
      How results were compared
      Study comparison: plant-source value; animal-source value is also summarized
      Additional measurement information
      Biomarker
      Measurement time
      Not confirmed.
Representative outcome and study details

Human studies reported between-group improvement in plasma tHcy.

Single-ingredient studies · Human studies · Population not specified · between-group comparison

1 publications linked to this result

  • Route, form, dose, or population details are incomplete, so the findings cannot be confirmed as directly comparable.
Data coverage and detailed study classifications

Paper counts are separated by research topic below. One paper may contribute to multiple findings.

Analysis status: Public-ready

Ingredient analysis date:

How the grade was determined: C

The 13.6 evidence score includes 0 independent human studies and 0 clinical studies in the representative benefit area. The C tier remains conservative because of limited repetition across independent human clinical studies, too few clinical findings with an explicit effect direction.

The grade is based mainly on the research area with the most evidence. It does not mean the same result was found in other areas.

Papers linked to this ingredient overall: 130

Papers linked to this topic 2 · distinct papers 2 · papers with a confirmed human comparison 1 · papers needing additional review 0

A publication may appear in more than one count. These numbers should not be added. Ingredient-wide papers, topic-linked papers, and sources in outcome groups use different scopes. Adding source counts may count the same paper more than once.

  • plasma tHcy: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 1
  • riboflavin: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0

What the research found

plasma tHcy

The study reported improvement in this measurement.

Controlled study in people · Single ingredient · Unspecified population

Between-group comparison

Analysis coverage and paper counts

1 paper · 1 measured outcome

Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.

riboflavin

A change was reported, but the comparison could not be confirmed.

Review · Unknown intervention · Unspecified population

Analysis coverage and paper counts

1 paper · 1 measured outcome

Review overlap with primary papers is unknown; counts stay separate.

Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.

How to read research findings

How should I read research findings?

Research guides

Side effects and combination findings

Findings from this ingredient alone are shown separately from those involving another supplement or medication.

No reviewed caution rules are available yet. Reported caution findings are shown below.

Findings to review with care

Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.

Side effects reported with this ingredient alone

Symptoms or adverse events reported in studies without another active ingredient.

apoptosis1 papers
Riboflavin deficiency is associated with adverse outcomes including growth retardation, increased mortality, liver damage, and apoptosis via mechanisms such as mitochondrial dysfunction, ER stress, ROS, and lipotoxicity.Human studies · Systematic review
adverse events1 papers
Vitamin B2 400 mg/day resulted in significantly fewer side effects (weight gain, dizziness, GI problems) compared to sodium valproate 500 mg/day in migraine patients (p = 0.005).Human studies · Randomized controlled trial